Grith Lykke Sørensen
Antibody for liver fibrosis
Professor Grith Lykke Sørensen from the University of Southern Denmark has vast ambitions.
She aims to develop a medication for liver fibrosis, a potentially lethal condition that currently lacks effective treatment. With a "Frontier Grant" of DKK 4.978.450, she will continue her mission to make a difference in the fight against the disease and bring hope to those currently without solutions.
Liver fibrosis is a deceitful disease that develops gradually and without symptoms until irreversible damage has occurred to the liver. The disease begins with the accumulation of fat in liver cells and chronic liver inflammation, a condition associated with obesity and type 2 diabetes.
As the disease progresses, fibrosis occurs, where the normal liver tissue is gradually replaced by scar tissue, affecting the liver's normal structure and function. At this advanced stage, the condition is called metabolic dysfunction-associated steatohepatitis (MASH). Here, large portions of the liver are replaced by scar tissue and irregular nodules of liver tissue with reduced function. Ultimately, this can lead to liver failure - a potentially deadly condition.
Professor Grith Lykke Sørensen from the University of Southern Denmark has vast ambitions. She aims to develop a medication for liver...
